NCT07505849 2026-04-01
ZR2 Versus R2 Regimen in the Treatment of Newly Diagnosed Follicular Lymphoma
Henan Cancer Hospital
Phase 2 Not yet recruiting
Clinical Trials
11 trialsNCT07360288 2026-01-22
TC011_FL_201
TICAROS Co., Ltd.
Phase 2 Not yet recruiting
NCT07299149 2025-12-23
ZGR in TN FL
Institute of Hematology & Blood Diseases Hospital, China
Phase 2 Not yet recruiting
NCT07197307 2025-09-29
CLEAR
Universität Münster
Phase 2 Not yet recruiting
NCT07191249 2025-09-24
A Phase 2, Multicenter, Open-Label Trial to Evaluate Efficacy and Safety of Subcutaneous (SC) Mosunetuzumab in Previously Untreated Low Tumor Burden Follicular Lymphoma (LTB-FL).
Tel-Aviv Sourasky Medical Center
Phase 2 Not yet recruiting
NCT07031700 2025-06-22
A Multicenter, Single-Arm, Open-Label, Phase II Trial of Mosunetuzumab in Combination With Tislelizumab for r/r FL
Tianjin Medical University Cancer Institute and Hospital
Phase 2 Not yet recruiting
NCT06918015 2025-04-15
Zanubrutinib Plus GCVP (Obinutuzumab, Cyclophosphamide, Vindesine, Prednisolone) in Previously Untreated Follicular Lymphoma
Zhejiang Cancer Hospital
Phase 2 Not yet recruiting
NCT06757894 2025-01-03
Efficacy and Safety of Zuberitamab Combined with Bendamustine, Followed by Monotherapy Maintenance, in Treatment-naïve Follicular Lymphoma
Sun Yat-sen University
Phase 2 Not yet recruiting
NCT06549335 2024-10-15
Zanubrutinib, Obinutuzumab and Lenalidomide (ZGR) in High-risk Treatment-naive Patients with Follicular Lymphoma (FL)
Ruijin Hospital
Phase 2 Not yet recruiting
NCT06368167 2024-04-16
A Phase II Study of SHR2554 in Patients With Relapsed or Refractory Follicular Lymphoma
Jiangsu HengRui Medicine Co., Ltd.
Phase 2 Not yet recruiting
NCT02194751 2021-04-08
Oncoquest-L Vaccine in Patients With Previously Untreated Stage III or IV, Asymptomatic, Non-bulky Follicular Lymphoma
XEME Biopharma Inc.
Phase 2 Not yet recruiting